Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jane Winter

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Leukemia & Lymphoma|July 16, 2009
Optimizing the CD34 + cell dose for reduced-intensity allogeneic hematopoietic stem cell transplantationJayesh Mehta, Jayesh Mehta, Olga Frankfurt, et al.
Blood Advances|January 18, 2024
A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimenReem Karmali, Carlos Galvez, Mehdi Hamadani, et al.
British Journal of Haematology|February 18, 2009
Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trialOwen A O'Connor, Craig Moskowitz, Carol Portlock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2010
Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypesOwen A O'Connor, Carol Portlock, Craig Moskowitz, et al.
Blood Advances|October 23, 2023
Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemiaBrian T Hill, Shuo Ma, Clive S Zent, et al.
Transplantation and Cellular Therapy|January 1, 2026
ASTCT Clinical Practice Recommendations for Transplantation in Classical Hodgkin LymphomaSairah Ahmed, Ambuj Kumar, Paul Carpenter, et al.
Clinical Lymphoma|July 2, 2005
Phase III randomized trial of patient-specific vaccination for previously untreated patients with follicular lymphoma in first complete remission: protocol summary and interim reportSattva S Neelapu, Barry L Gause, Daniel A Nikcevich, et al.
Blood Cancer Journal|March 27, 2025
Double hit & double expressor lymphomas: a multicenter analysis of survival outcomes with CD19-directed CAR T-cell therapyReem Karmali, Geoffrey Shouse, Pallawi Torka, et al.
Blood Advances|March 26, 2024
Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapyReem Karmali, Rushad Machhi, Narendranath Epperla, et al.
Blood Advances|September 12, 2022
Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHLJoanna Zurko, Imran Nizamuddin, Narendranath Epperla, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Leukemia & Lymphoma|July 16, 2009
Optimizing the CD34 + cell dose for reduced-intensity allogeneic hematopoietic stem cell transplantationJayesh Mehta, Jayesh Mehta, Olga Frankfurt, et al.
Blood Advances|January 18, 2024
A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimenReem Karmali, Carlos Galvez, Mehdi Hamadani, et al.
British Journal of Haematology|February 18, 2009
Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trialOwen A O'Connor, Craig Moskowitz, Carol Portlock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2010
Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypesOwen A O'Connor, Carol Portlock, Craig Moskowitz, et al.
Blood Advances|October 23, 2023
Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemiaBrian T Hill, Shuo Ma, Clive S Zent, et al.
Transplantation and Cellular Therapy|January 1, 2026
ASTCT Clinical Practice Recommendations for Transplantation in Classical Hodgkin LymphomaSairah Ahmed, Ambuj Kumar, Paul Carpenter, et al.
Clinical Lymphoma|July 2, 2005
Phase III randomized trial of patient-specific vaccination for previously untreated patients with follicular lymphoma in first complete remission: protocol summary and interim reportSattva S Neelapu, Barry L Gause, Daniel A Nikcevich, et al.
Blood Cancer Journal|March 27, 2025
Double hit & double expressor lymphomas: a multicenter analysis of survival outcomes with CD19-directed CAR T-cell therapyReem Karmali, Geoffrey Shouse, Pallawi Torka, et al.
Blood Advances|March 26, 2024
Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapyReem Karmali, Rushad Machhi, Narendranath Epperla, et al.
Blood Advances|September 12, 2022
Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHLJoanna Zurko, Imran Nizamuddin, Narendranath Epperla, et al.
Pageof 3